Daniel Hume Acquires Shares of TG Therapeutics, Inc.

On June 11, 2026, Daniel Hume, an insider at TG Therapeutics, Inc. (NasdaqCM: TGTX), purchased 8,325 shares of the company. The transaction was recorded at a price of $0.00 per share, indicating it may have been a stock grant or similar transaction. Shares of TG Therapeutics traded at $49.52 on that day.

Insider Buying and Selling at TG Therapeutics, Inc.

Several insiders at TG Therapeutics made similar transactions on June 11, 2026. Yann Echelard, Sagar Lonial, Kenneth Hoberman, and Laurence Charney each acquired 8,325 shares. These transactions were not part of any pre-planned trading program. Earlier in the year, on January 29, 2026, Laurence Charney sold 13,197 shares.

Other Institutional Activity in TG Therapeutics

BlackRock, Inc. increased its holdings in TG Therapeutics, adding 404,468 shares to reach a total of 22,252,930 shares valued at approximately $739.2 million. State Street Corp also boosted its position by 169,767 shares, bringing its total to 8,649,766 shares worth about $287.3 million. Soleus Capital Management, L.P. made a significant addition of 890,007 shares, ending with 4,029,319 shares valued at $133.9 million.

TG Therapeutics, Inc. Stock Down 8.2%

Shares of TG Therapeutics, Inc. were trading around $49.52. The company has a market cap of about $7.58 billion and a P/E ratio of 17.31. Its beta is 1.675, indicating higher volatility than the overall market. The stock's 52-week range is between $25.28 and $50.41, with a 50-day moving average of $38.32 and a 200-day moving average of $33.20.

Recent Earnings

TG Therapeutics reported revenue of $700.35 million, with a robust growth rate of 69.6%. The company achieved a net margin of 65.95% and a return on equity of 112.6%. The next earnings report is expected on August 3, 2026.

Analysts Set New Price Targets

On May 27, 2026, HC Wainwright & Co. reiterated a 'buy' rating for TG Therapeutics, setting a price target of $70. JP Morgan maintained its 'buy' rating with a target of $46 on February 2, 2026. The analyst consensus is a 'buy' with a mean target price of $48, based on seven analyst opinions.

About TG Therapeutics, Inc.

TG Therapeutics, Inc., headquartered in Morrisville, North Carolina, is a biopharmaceutical company focused on developing treatments for B-cell mediated diseases like multiple sclerosis. Its flagship product, BRIUMVI, is used for treating relapsing forms of multiple sclerosis. The company is also working on various investigational medicines and has partnerships with several international pharmaceutical firms. The CEO is Michael S. Weiss.

Bottom Line

Daniel Hume's recent purchase of shares in TG Therapeutics adds to the insider activity at the company. With a strong market cap and solid financial performance, TG Therapeutics remains a key player in the biotechnology sector. The insider transactions reflect ongoing confidence in the company's strategic direction, although it's important to remember that these filings are backward-looking and may not reflect current positions.